Chroma Therapeutics Overview
- Year Founded
-
2000
- Status
-
Out of Business
- Employees
-
51
- Latest Deal Type
-
Out of Business
Chroma Therapeutics General Information
Description
Provider of novel small molecule drugs products created for cancer treatment. The company engages in discovery and development of small molecule drugs based upon chromatin biology and cell accumulation approaches which aims at the treatment of high-prevalence cancers and inflammatory disorders.
Contact Information
Website
www.chromatherapeutics.comCorporate Office
- 93 Innovation Drive
- Milton Park, Abingdon
- Milton OX14 4RY
- England, United Kingdom
Corporate Office
- 93 Innovation Drive
- Milton Park, Abingdon
- Milton OX14 4RY
- England, United Kingdom
Chroma Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Out of Business | 01-Aug-2018 | Completed | Out of Business | |||
| 6. Mezzanine | 06-May-2010 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series D) | 23-Jun-2009 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series C) | 03-Apr-2006 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series B) | 14-Jun-2004 | Completed | Startup | |||
| 2. Early Stage VC (Series A) | $2.18M | Completed | Startup | |||
| 1. Seed Round | 30-Oct-2001 | $2.18M | $2.18M | Completed | Startup |
Chroma Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B1 | ||||||||
| Series B | 10,629,340 | $0.016285 | $1.91 | $1.91 | 1x | $1.91 | 21.26% | |
| Series A | 1,766,874 | $0.016285 | $1.63 | $1.63 | 1x | $1.63 | 3.53% |
Chroma Therapeutics Comparisons
Industry
Financing
Details
Chroma Therapeutics Competitors (21)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals | Formerly VC-backed | Boston, MA | ||||
| SpliSense | Venture Capital-Backed | Jerusalem, Israel | ||||
| Ability Pharma | Private Equity-Backed | Barcelona, Spain | ||||
| Bristol-Myers Squibb | Corporation | Princeton, NJ | ||||
| Nektar Therapeutics | Formerly VC-backed | San Francisco, CA |
Chroma Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Chroma Therapeutics Patents
Chroma Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-201322098-D0 | Mek-1, 2 kinase inhibitors | Inactive | 13-Dec-2013 | ||
| GB-201306881-D0 | Chemical compounds | Inactive | 16-Apr-2013 | ||
| GB-201306901-D0 | Combination | Inactive | 16-Apr-2013 | ||
| GB-201218640-D0 | Chemical compounds | Inactive | 17-Oct-2012 | ||
| JP-2015534974-A | Tert-butyl n- [2- {4- [6-amino-5- (2,4-difluorobenzoyl) -2-oxopyridin-1 (2h) -yl] -3,5-difluorophenyl} ethyl)- l-alaninate or a pharmaceutically acceptable salt, hydrate or solvate thereof | Active | 17-Oct-2012 | C07D213/73 |
Chroma Therapeutics Executive Team (7)
| Name | Title | Board Seat |
|---|---|---|
| Richard Bungay | Chief Executive Officer, Secretary & Board Member |
Chroma Therapeutics Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Richard Bungay | Self | Chief Executive Officer, Secretary & Board Member |
Chroma Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Chroma Therapeutics FAQs
-
When was Chroma Therapeutics founded?
Chroma Therapeutics was founded in 2000.
-
Who is the founder of Chroma Therapeutics?
Steve Pierson is the founder of Chroma Therapeutics.
-
Who is the CEO of Chroma Therapeutics?
Richard Bungay is the CEO of Chroma Therapeutics.
-
Where is Chroma Therapeutics headquartered?
Chroma Therapeutics is headquartered in Milton, United Kingdom.
-
What is the size of Chroma Therapeutics?
Chroma Therapeutics has 51 total employees.
-
What industry is Chroma Therapeutics in?
Chroma Therapeutics’s primary industry is Biotechnology.
-
Is Chroma Therapeutics a private or public company?
Chroma Therapeutics is a Private company.
-
What is Chroma Therapeutics’s current revenue?
The current revenue for Chroma Therapeutics is .
-
How much funding has Chroma Therapeutics raised over time?
Chroma Therapeutics has raised $108M.
-
Who are Chroma Therapeutics’s competitors?
Vertex Pharmaceuticals, SpliSense, Ability Pharma, Bristol-Myers Squibb, and Nektar Therapeutics are some of the 21 competitors of Chroma Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
